Immunotherapy in the treatment of lymphoma

Table 2 Antibody-drug conjugate studies

Drug [Ref.]	Target	No. of patients	Study design	Study phase	Results
Brentuximab-vedotin	CD30
[10,58]		102	R/R cHL	2	ORR/CR: 72%/33% PFS 9.3 mo; OS 40.5 mo; AEs: PSN 42%, nausea 35%, fatigue 34%
[59,60]		329	R/R high-risk cHL maint BV vs Pbo	3	5-yr PFS rate 59% vs 41% (HR 0.52) OS: NR AEs: PSN (90% resolved)
[61]		1334	Untreated cHL CS III/IV BV + AVD vs ABVD	3	2-yr mPFS rate: 82.1% vs 77.2% (HR 0.77, P = 0.04) AEs: Neutropenia 58% vs 45%, PSN 67% vs 43%, PN 1% vs 3%
[62]		131	R/R CTCL or cALCL; vs MTX or BV	3	ORR4: 56.3% vs 12.5% (P < 0.0001); EFS: 9.4 mo vs 2.3 mo (HR 0.28, P < 0.0001) Grade ≥ 3 AEs: 41% vs 47%; PSN: 67% vs 6%
[63]		58	R/R ALCL	2	ORR/CR: 86%/66%; 5-yr OS rate: 60%, 5-yr OS rate (in CR vs non-CR): 79% vs 25%
[64]		601	Untreated CD30+ sALCL; BV + CHP vs CHOP	3	PFS: 48.2 mo vs 20.8 mo (HR 0.71, P = 0.011); OS: NR vs NR (HR 0.66, P = 0.024) AEs: febrile neutropenia 18% vs 15%, PSN 52% vs 55%
Polatuzumab vedotin[65]	CD79b	80	R/R DLBCL; PV + R + Benda vs R + Benda	2	CR: 40% vs 17.5% PFS: 9.5 mo vs 3.7 mo (HR 0.63, P < 0.001) Grade ≥ 3 AEs: Anemia 28.2% vs 17.9%, Neutropenia 46.2% vs 33.3% Thrombocytopenia 41.0% vs 23.1%
Moxetumomab-pasudotox[68]	CD22	80	R/R HCL	2	ORR: 75% CR: 30% (85% MRD-); AEs: Edema 39%, nausea 35%, fatigue 34%, headache 33%

ABVD: Doxorubicin, bleomycin, vinblastine, dacarbazine; AE: Adverse event; AE: Adverse event; ALCL: Anaplastic large-cell lymphoma; AVD: Doxorubicin, bleomycin, vinblastine, dacarbazine; Benda: Bendamustin; BV: Brentuximab vedotin; cHL: Classic Hodgkin lymphoma; CHOP: Cyclophosphamide, adriamycin, oncovin, prednisone; CHP: Cyclophosphamide, adriamycin, prednisone; CR: Complete response; CS: Clinical stage; CTCL: Cutaneous large-cell lymphoma; DLBCL: Diffuse large b-cell lymphoma; EFS: Event-free survival; HCL: Hairy cell leukemia; maint: MAINTENANCE; MRD: Minimal residual disease. MTX: Methotrexate; NR: Not reached; ORR: Objective response rate; OS: Overall survival; Pbo: Placebo; PFS: Progression-free survival; PNS: Peripheral neuropathy syndrome; PV: Polatuzumab vedotin; R: Rituximab; R/R: Relapsed/refractory.